<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02083991</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000451-13</org_study_id>
    <nct_id>NCT02083991</nct_id>
  </id_info>
  <brief_title>Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation</brief_title>
  <acronym>SAILOR</acronym>
  <official_title>A Controlled Randomized, Open-label, Multi-centre Study Evaluating if a Steroid-free Immunosuppressive Protocol, Based ATG-induction, Low Tacrolimus-dose and Therapeutic Drug Monitoring of Mycophenolate Mofetil, Reduces the Incidence of New Onset Diabetes After Transplantations, in Comparison With Standard Steroid-based Protocol With Low-dose Tacrolimus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balancing immunosuppressive treatment in organ transplantation in order to achieve effective&#xD;
      prevention of rejection on one side and avoidance of negative side effects on the other side&#xD;
      is a major challenge, leading to developing different immunosuppressive protocols.&#xD;
      Cornerstones of immunosuppressive treatment such as Corticosteroids (CS) and Calcineurin&#xD;
      Inhibitors (CNI) are known to cause an increased incidence of diabetes, cardiovascular&#xD;
      morbidity, nephrotoxicity and malignancies.&#xD;
&#xD;
      The investigators believe that both avoidance of CS and minimization of CNI, while using&#xD;
      Anti-ThymocyteGlobuline(ATG) induction (instead of interleucin-2 receptor blockers) and&#xD;
      mycofenolate mofetil(MMF) therapeutic drug monitoring is going to reduce negative side&#xD;
      effects, without increased rejection frequency in renal transplanted patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT)</measure>
    <time_frame>12 month after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of NODAT</measure>
    <time_frame>3, 6, 24 month after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Freedom from acute rejection, graft and patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Evaluated by measured glomerular filtration rate (mGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection and chronic changes</measure>
    <time_frame>12 months</time_frame>
    <description>Analysed by protocol biopsies, evaluated by the Banff system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertension</measure>
    <time_frame>3, 12, 24 months</time_frame>
    <description>Standardized measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive treatment</measure>
    <time_frame>3, 12, 24 months</time_frame>
    <description>Number and type of antihypertensive drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid lowering drugs</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Number and type of lipid lowering drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibody-mediated rejection</measure>
    <time_frame>12, 24 months</time_frame>
    <description>Analysed by biopsies, evaluated by the Banff system, and by donor-specific HLA antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of cardiovascular complications and events.</measure>
    <time_frame>10 days, 3, 12, 24 months</time_frame>
    <description>Collecting Adverse Events (AE) reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of malignancy.</measure>
    <time_frame>6, 12, 24 months</time_frame>
    <description>Collecting AE reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of infections</measure>
    <time_frame>10 days, 3, 6, 12, 24 months</time_frame>
    <description>Collecting AE reports</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Steroid-free low TAC-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.&#xD;
Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard low-TAC arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.&#xD;
Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon</intervention_name>
    <arm_group_label>Standard low-TAC arm</arm_group_label>
    <arm_group_label>Steroid-free low TAC-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First or second single kidney (cadaveric or living donors) transplant recipients.&#xD;
&#xD;
          -  Considered for a standard immunosuppressive protocol.&#xD;
&#xD;
          -  Must be capable of giving written informed connect for participation in the study for&#xD;
             24 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus or plasma glucose &gt;11,1 at admission.&#xD;
&#xD;
          -  Receiving steroids at the time of transplantation or likely to need steroids after&#xD;
             transplantation.&#xD;
&#xD;
          -  Multiorgan transplants and/or previously transplanted with any other organ than&#xD;
             kidney.&#xD;
&#xD;
          -  Panel reacting antibodies(PRA) &gt;25% in most recent test or considered to be of high&#xD;
             risk for rejection which requires an enhanced immunosuppression.&#xD;
&#xD;
          -  Renal transplants from HLA-identical sibling.&#xD;
&#xD;
          -  Hypersensitivity to, or disability to take immunosuppressive drugs.&#xD;
&#xD;
          -  Blood group(ABO)-incompatible transplants.&#xD;
&#xD;
          -  Unlikely to comply with the study requirements.&#xD;
&#xD;
          -  Transplant from donor positive for HIV, HBsAg, Hepatitis C.&#xD;
&#xD;
          -  Female of childbearing potential planing/being pregnant or unwilling to use&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Lindn√©r, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Transplant Institute, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2014</study_first_posted>
  <last_update_submitted>January 3, 2021</last_update_submitted>
  <last_update_submitted_qc>January 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NODAT</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Corticosteroids avoidance</keyword>
  <keyword>CNI minimization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

